Navigation Links
Sixth U.S. Patent Issued to Dyadic International
Date:10/13/2010

JUPITER, Fla., Oct. 13 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (Pink Sheets: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,794,962 by the United States Patent and Trademark Office ("USPTO").

(Logo: http://www.newscom.com/cgi-bin/prnh/20091214/DYADICLOGO)

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO)

The invention embodied by this patent provides a method for the expression and subsequent screening of DNA libraries in filamentous fungal hosts which may help speed up the discovery of novel genes and development of their corresponding enzymes and proteins. The newly issued patent is accessible on the USPTO's website at www.uspto.gov or on Dyadic's website at www.dyadic.com.

This patent is the sixth U.S. patent issued to Dyadic adding to its portfolio of 60 international patents and more than 40 pending patent applications worldwide which cover various features of Dyadic's proprietary technologies.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "As with our entire patent portfolio, we believe that this patent will help us further enhance our intellectual property protection of Dyadic's cutting edge technologies, provide additional potential licensing opportunities and strengthen our competitive market position."

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
2. Connectyx Announces MedFlash(R) Sixth Man Fan Promotion in Conjunction With Walgreens and The Orlando Magic
3. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
4. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
5. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
6. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
7. ArtJen Announces Major Clinical Trial of Its Patented Weight Loss Product FBCx
8. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
9. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
10. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
11. Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
Breaking Medicine News(10 mins):